Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
Xiaoli Wang, … , John Mascarenhas, Ronald Hoffman
Xiaoli Wang, … , John Mascarenhas, Ronald Hoffman
Published March 8, 2022
Citation Information: JCI Insight. 2022;7(8):e156534. https://doi.org/10.1172/jci.insight.156534.
View: Text | PDF
Research Article Oncology Stem cells

Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase

  • Text
  • PDF
Abstract

Chronic myeloproliferative neoplasms (MPN) frequently evolve to a blast phase (BP) that is almost uniformly resistant to induction chemotherapy or hypomethylating agents. We explored the functional properties, genomic architecture, and cell of origin of MPN-BP initiating cells (IC) using a serial NSG mouse xenograft transplantation model. Transplantation of peripheral blood mononuclear cells (MNC) from 7 of 18 patients resulted in a high degree of leukemic cell chimerism and recreated clinical characteristics of human MPN-BP. The function of MPN-BP ICs was not dependent on the presence of JAK2V617F, a driver mutation associated with the initial underlying MPN. By contrast, multiple MPN-BP IC subclones coexisted within MPN-BP MNCs characterized by different myeloid malignancy gene mutations and cytogenetic abnormalities. MPN-BP ICs in 4 patients exhibited extensive proliferative and self-renewal capacity, as demonstrated by their ability to recapitulate human MPN-BP in serial recipients. These MPN-BP IC subclones underwent extensive continuous clonal competition within individual xenografts and across multiple generations, and their subclonal dynamics were consistent with functional evolution of MPN-BP IC. Finally, we show that MPN-BP ICs originate from not only phenotypically identified hematopoietic stem cells, but also lymphoid-myeloid progenitor cells, which were each characterized by differences in MPN-BP initiating activity and self-renewal capacity.

Authors

Xiaoli Wang, Raajit K. Rampal, Cing Siang Hu, Joseph Tripodi, Noushin Farnoud, Bruce Petersen, Michael R. Rossi, Minal Patel, Erin McGovern, Vesna Najfeld, Camelia Iancu-Rubin, Min Lu, Andrew Davis, Marina Kremyanskaya, Rona Singer Weinberg, John Mascarenhas, Ronald Hoffman

×

Figure 2

MPN-BP SC function following serial transplantation.

Options: View larger image (or click on image) Download as PowerPoint
MPN-BP SC function following serial transplantation.
(A–C) Human CD45+ c...
(A–C) Human CD45+ cell chimerism (A) and leukemic cell burden (percentage of hCD34+ [B]/hCD45dimCD33+ cells [C]) were determined by flow cytometry of the BM of primary (P0), secondary (P1), tertiary (P2), and quaternary (P3) recipient mice receiving Pt 2 sample. Serially transplanted recipient mice were sacrificed 8 weeks after transplantation. Numbers of hCD34+ cells contained in the transplanted grafts are: Primary, 1.25 × 106; P0, 4.6 × 105; P1, 4.5 × 105; P2, 2 × 105. Bars indicate the mean in A–C. Data are represented as mean ± SEM. n each =3 mice. *P < 0.05, **P < 0.01, ***P < 0.001 by ANOVA.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts